Time‐to‐event modelling of effect of codrituzumab on overall survival in patients with hepatocellular carcinoma
2018
Aims
Codrituzumab (GC33) is a recombinant, humanized mAb that binds to glypican‐3 (GPC3), an oncofetal protein highly expressed in hepatocellular carcinoma (HCC). This investigation aimed to identify clinically relevant factors that may affect the overall survival (OS) in HCC patients treated with codrituzumab and to quantitatively annotate their effects.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
15
References
2
Citations
NaN
KQI